This phase IV multicenter clinical trial, the PROVE-HF trial in the US, was designed to determine the NT-proBNP-lowering effects of sacubitril/valsartan together with the change in cardiac structure and function in HF patients with reduced EF. Here, NPPB is linked to hydrops fetalis.